Hereditary Gastric Cancer Panel, Sequencing and Deletion/Duplication

Pathogenic germline variants in multiple genes have been implicated in hereditary gastric cancer. Hereditary gastric cancer syndromes are often characterized by an early age of disease onset (typically before age 50) and multiple, multifocal, and/or similar cancers in a single individual or one or more closely related family members.

Genetics

Genes

Refer to the Genes Tested table for genes included in the panel.

Etiology

Approximately 5-10% of gastric cancers are associated with a hereditary cause.

Inheritance

- Typically autosomal dominant (AD)
- Some genes are also associated with autosomal recessive (AR) childhood cancer predisposition or other syndromes.

Test Interpretation

Contraindications for Ordering

- For individuals with a suspected diagnosis of Lynch syndrome, consider testing specific to Lynch syndrome as some relevant variants are not included on this panel. Refer to Lynch Syndrome - Hereditary Nonpolyposis Colorectal Cancer (HNPCC) for more information.
- This test should not be ordered to detect somatic variants associated with malignancy because sensitivity for mosaic variants is low with the methodology used for germline assays.
- Individuals with hematological malignancy and/or a previous allogeneic bone marrow transplant should not undergo molecular genetic testing on a peripheral blood specimen.
  - Testing cultured fibroblasts is required for the accurate interpretation of test results.

Featured ARUP Testing

To compare directly to other hereditary cancer panels offered by ARUP Laboratories, refer to the ARUP Hereditary Cancer Panel Comparison table.

Hereditary Gastric Cancer Panel, Sequencing and Deletion/Duplication 3005963

Method: Massively Parallel Sequencing/Sequencing/Multiplex Ligation-dependent Probe Amplification

- Recommended test to confirm a hereditary cause of gastric cancer in individuals with a personal or family history of gastric cancer
- Testing minors for adult-onset conditions is not recommended; testing will not be performed in minors without prior approval. For additional information, please contact an ARUP genetic counselor at 800-242-2787 ext. 2141.

If a familial sequence variant has been previously identified, targeted sequencing for that variant may be appropriate; refer to the Laboratory Test Directory for additional information.
Methodology

This test is performed using the following sequence of steps:

- Selected genomic regions, primarily coding exons and exon-intron boundaries from the targeted genes, are isolated from extracted genomic DNA using a probe-based hybrid capture enrichment workflow.
- Enriched DNA is sequenced by massively parallel sequencing (MPS; also known as next generation sequencing [NGS]) followed by paired-end read alignment and variant calling using a custom bioinformatics pipeline. The pipeline includes an algorithm for the detection of large (single exon-level or larger) deletions and duplications.
- Sanger sequencing is performed as necessary to fill in regions of low coverage and confirm variant calls.
- Large deletion/duplication calls made using MPS are confirmed by an orthogonal exon-level microarray when sample quality and technical conditions allow.
- Long-range polymerase chain reaction (PCR) testing followed by nested Sanger sequencing is performed on the following gene and exons:
  - PMS2 (NM_000535) 11, 12, 13, 14, 15
- Bidirectional Sanger sequencing is performed on the following genes and exons:
  - MSH2 (NM_000251) 5
  - PMS2 (NM_000535) 7
- Multiplex ligation-dependent probe amplification (MLPA) testing is performed on the following genes to call exon-level deletions and duplications:
  - PMS2 (NM_000535)

Sensitivity/Specificity

Clinical Sensitivity

Variable; dependent on phenotype

Analytic Sensitivity

<table>
<thead>
<tr>
<th>Variant Class</th>
<th>Analytic Sensitivity (PPA) Estimatea (%) and 95% Credibility Region (%)</th>
<th>Analytic Specificity (NPA) Estimate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNVs</td>
<td>&gt;99 (96.9-99.4)</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Deletions 1-10 bp</td>
<td>93.8 (84.3-98.2)</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Insertions 1-10 bp</td>
<td>94.8 (86.8-98.5)</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Exon-levelc deletions</td>
<td>97.8 (90.3-99.8) [2 exons or larger] 62.5 (38.3-82.6) [single exon]</td>
<td>&gt;99.9</td>
</tr>
</tbody>
</table>

*aPPA values are derived from larger methods-based MPS and/or Sanger validations. These values do not apply to testing performed by MLPA unless otherwise indicated.

bVariants greater than 10 bp may be detected, but the analytic sensitivity may be reduced.

cIn most cases, a single exon deletion or duplication is less than 450 bp and 3 exons span a genomic region larger than 700 bp.

bp, base pairs; NPA, negative percent agreement; PPA, positive percent agreement; SNVs, single nucleotide variants
<table>
<thead>
<tr>
<th>Variant Class</th>
<th>Analytic Sensitivity (PPA) Estimate(^a) (%) and 95% Credibility Region (%)</th>
<th>Analytic Specificity (NPA) Estimate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exon-level(^c) duplications</td>
<td>83.3 (56.4-96.4) [3 exons or larger]</td>
<td>&gt;99.9</td>
</tr>
<tr>
<td>Exon-level deletions/duplications (MLPA)</td>
<td>&gt;99</td>
<td>&gt;99</td>
</tr>
</tbody>
</table>

\(^a\) PPA values are derived from larger methods-based MPS and/or Sanger validations. These values do not apply to testing performed by MLPA unless otherwise indicated.

\(^b\) Variants greater than 10 bp may be detected, but the analytic sensitivity may be reduced.

\(^c\) In most cases, a single exon deletion or duplication is less than 450 bp and 3 exons span a genomic region larger than 700 bp.

bp, base pairs; NPA, negative percent agreement; PPA, positive percent agreement; SNVs, single nucleotide variants

**Limitations**

- A negative result does not exclude a heritable form of gastric cancer or another cancer.
- Diagnostic errors can occur due to rare sequence variations.
- The interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation.
- The following will not be evaluated:
  - Variants outside the coding regions and intron-exon boundaries of the targeted gene(s)
  - Regulatory region and deep intronic variants
  - Breakpoints of large deletions/duplications
  - Sequence variants in *EPCAM*
  - The following exons are not sequenced due to the technical limitations of the assay:
    - *APC* (NM_001354896) 12
    - *APC* (NM_001354898, NM_001354904) 2
    - *APC* (NM_001354900) 11
  - The following may not be detected:
    - Deletions/duplications/insertions of any size by MPS
    - Large duplications less than 3 exons in size
    - Noncoding transcripts
    - Single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement.
    - Low-level somatic variants
    - Certain other variants due to technical limitations in the presence of pseudogenes and/or repetitive/homologous regions
    - Deletions/duplications in the following exons:
      - *APC* (NM_001354896) 12
      - *APC* (NM_001354898, NM_001354904) 2
      - *APC* (NM_001354900) 11
      - *BMPR1A* (NM_004329) 12-13
      - *CDH1* (NM_001317185) 10
      - *CTNNA1* (NM_001290307) 19
      - *CTNNA1* (NM_001324002, NM_001324004) 13
      - *CTNNA1* (NM_001324003) 15
      - *CTNNA1* (NM_001324005) 16
Genes Tested

To compare directly to other hereditary cancer panels offered by ARUP Laboratories, refer to the ARUP Hereditary Cancer Panel Comparison table.

<table>
<thead>
<tr>
<th>Gene</th>
<th>MIM Number</th>
<th>Disorder/Associated Cancer(s)/Tumor(s)</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>APC</td>
<td>611731</td>
<td>FAP, AFAP, GAPPS, Colorectal adenomas and cancer, duodenal adenomas and cancer, gastric fundic gland polyps, medulloblastoma, osteomas, pancreatic, thyroid, and others</td>
<td>AD</td>
</tr>
<tr>
<td>BMPR1A</td>
<td>601299</td>
<td>JPS, Colorectal, juvenile polyps, small intestine, stomach</td>
<td>AD</td>
</tr>
<tr>
<td>CDH1</td>
<td>192090</td>
<td>HDGC, Diffuse gastric, lobular breast</td>
<td>AD</td>
</tr>
<tr>
<td>CTNNA1</td>
<td>116805</td>
<td>Breast, stomach</td>
<td>AD</td>
</tr>
<tr>
<td>EPCAM</td>
<td>185535</td>
<td>Lynch syndrome/HNPCC, Brain, colorectal, endometrial, ovarian, pancreatic, prostate, renal pelvis and/or ureter, stomach, and others</td>
<td>AD</td>
</tr>
<tr>
<td>MLH1</td>
<td>120436</td>
<td>Lynch syndrome/HNPCC, Brain, colorectal, endometrial, ovarian, pancreas, prostate, renal pelvis and/or ureter, stomach, and others</td>
<td>AD</td>
</tr>
<tr>
<td>MSH2</td>
<td>609309</td>
<td>Lynch syndrome/HNPCC, Brain, colorectal, endometrial, ovarian, pancreas, prostate, renal pelvis and/or ureter, stomach, and others</td>
<td>AD</td>
</tr>
<tr>
<td>MSH6</td>
<td>600678</td>
<td>Lynch syndrome/HNPCC</td>
<td>AD</td>
</tr>
</tbody>
</table>

"Association is suggested but not well-established at this time.

AFAP, attenuated familial adenomatous polyposis; CMMRD, constitutional mismatch repair deficiency; CNS, central nervous system; FAP, familial adenomatous polyposis; GAPPS, gastric adenocarcinoma and proximal polyposis of the stomach; HDGC, hereditary diffuse gastric cancer; HHT, hereditary hemorrhagic telangiectasia; HNPCC, hereditary nonpolyposis colorectal cancer; JPS, juvenile polyposis syndrome; LFS, Li-Fraumeni syndrome; PJS, Peutz-Jeghers syndrome
<table>
<thead>
<tr>
<th>Gene</th>
<th>MIM Number</th>
<th>Disorder/Associated Cancer(s)/Tumor(s)</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>PMS2</td>
<td>600259</td>
<td>Brain, colorectal, endometrial, ovarian, pancreas, prostate, renal pelvis and/or ureter, stomach, and others</td>
<td>AR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CMMRD</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lynch syndrome/HNPCC</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Brain, colorectal, endometrial, ovarian, pancreas, prostate, renal pelvis and/or ureter, stomach, and others</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CMMRD</td>
<td></td>
</tr>
<tr>
<td>SMAD4</td>
<td>600993</td>
<td>JPS, HHT syndrome</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colorectal, juvenile polyps, small intestine, and stomach</td>
<td></td>
</tr>
<tr>
<td>STK11</td>
<td>602216</td>
<td>PJS</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast, cervix, colorectal, endometrial, lung, ovarian (sex cord with annular tubules), pancreas, Peutz-Jeghers-type hamartomatous polyps, small intestine, stomach, testes</td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>191170</td>
<td>LFS</td>
<td>AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adrenocortical carcinoma, breast, choroid plexus carcinoma, CNS, colorectal, melanoma, osteosarcoma, pancreas, prostate, renal, rhabdomyosarcoma, soft tissue sarcoma, stomach, thyroid, and others</td>
<td></td>
</tr>
</tbody>
</table>

*Association is suggested but not well-established at this time.

AFAP, attenuated familial adenomatous polyposis; CMMRD, constitutional mismatch repair deficiency; CNS, central nervous system; FAP, familial adenomatous polyposis; GAPPS, gastric adenocarcinoma and proximal polyposis of the stomach; HDGC, hereditary diffuse gastric cancer; HHT, hereditary hemorrhagic telangiectasia; HNPCC, hereditary nonpolyposis colorectal cancer; JPS, juvenile polyposis syndrome; LFS, Li-Fraumeni syndrome; PJS, Peutz-Jeghers syndrome

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology. 500 Chipeta Way, Salt Lake City, UT 84108
(800) 522-2787 | (801) 583-2787 | aruplab.com | arupconsult.com
Content Review December 2022 | Last Update September 2023